Hofseth Biocare ASA: SUCCESSFULLY COMPLETED SEED ROUND CAPITAL RAISE IN HBC IMMUNOLOGY LLC AT $20M VALUATION FOR THE DEVELOPMENT OF A NEW PROSTATE CANCER CO-THERAPY
17 août 2023 02h58 HE
|
Hofseth Biocare ASA
HBC Immunology LLC (“HBCI” or the “Company”), a majority owned subsidiary of Hofseth BioCare ASA (“HBC”), has successfully completed the required minimum seed capital financing of approx. USD 900,000...
Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
14 juil. 2023 08h33 HE
|
Hofseth Biocare ASA
Christel Elise Kanli, primary insider and CFO/COO in Hofseth BioCare ASA («HBC») has today purchased 74,000 shares in HBC at an average price of approx. NOK 2.70 per share. As a result of the...
Hofseth Biocare ASA: ADVANCING THE TREATMENT OF PROSTATE CANCER WITH PUBLICATION OF FTH1 RESEARCH ABSTRACT AHEAD OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING
30 mai 2023 02h40 HE
|
Hofseth Biocare ASA
HBC is pleased to announce the online publication of its abstract titled “Antiproliferative activity of marine-derived oligopeptides combined with androgen receptor inhibition in preclinical cancer...
Hofseth Biocare ASA: SPIN-OFF OF PROSTATE CANCER CO-TREATMENT PROJECT
15 mai 2023 01h50 HE
|
Hofseth Biocare ASA
Hofseth Biocare ASA ("HBC" or the "Company") today announces the decision to transfer its prostate cancer co-treatment project (the "Project") to a new US entity to be called HBC Immunology Inc....
Hofseth BioCare ASA: FIRST QUARTER 2023 FINANCIAL REPORT
12 mai 2023 01h56 HE
|
Hofseth Biocare ASA
The first quarter of 2023 shows a very good development for HBC. Revenues came in at NOK 44m vs NOK 30m last year, a growth of 48 % YoY and 32 % QoQ. The underlying growth we are seeing is coming from...
Hofseth Biocare ASA: COMPLETED ANNUAL GENERAL MEETING
28 avr. 2023 08h09 HE
|
Hofseth Biocare ASA
Hofseth BioCare ASA held its Annual General Meeting on 28 April 2023. 253,351,609 shares, amounting to 64.13 per cent of the share capital, were represent in the meeting or by proxy. All proposals...
Hofseth Biocare ASA: DISCLOSURE OF VOTING PROXIES
28 avr. 2023 05h32 HE
|
Hofseth Biocare ASA
Reference is made to the notice from Hofseth BioCare ASA (the "Company") for an annual general meeting to be held on 28 April 2023 (the "AGM"). Torill Standal Eliassen, board member of the Company,...
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2023
13 avr. 2023 17h56 HE
|
Hofseth Biocare ASA
The Annual General Meeting of Hofseth BioCare ASA will be held at the company's premises at Kipervikgata 13, 6003 Ålesund, on 28 April 2023 at 13:00 CET. The notice of the Annual General Meeting...
Hofseth Biocare ASA: HBC ANNUAL REPORT 2022
31 mars 2023 02h00 HE
|
Hofseth Biocare ASA
The Board of Directors of Hofseth BioCare ASA (“HBC”) has approved the financial statements for 2022 and the Company has today published the Annual Report and Sustainability Report for 2022. Please...
Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
28 févr. 2023 02h00 HE
|
Hofseth Biocare ASA
Bomi Framroze Holding AS, a close associate of primary insider and Chief Scientific Officer Dr. Bomi Framroze in Hofseth Biocare ASA ("HBC"), has on 27 February 2023 purchased 200,000 shares in HBC at...